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Objective: To investigate the effect of timing of dexamethasone administration on auditory hair cell survival
following an ototoxic insult with kanamycin and furosemide.
Study design: Controlled experimental study.
Setting: Translational science experimental laboratory.
Methods: 5–6 week old CBA/CaJ mice, divided into 6 groups, were injected with kanamycin (1 mg/g SC) followed
by furosemide (0.5 mg/g IP). Dexamethasone (0.1 mg/g IP) was injected at either 1 hour prior to insult, +1 hr, +6 hr,
+12 hr, or +72 hr post insult. Temporal bones harvested on day 7 underwent Organ of Corti dissection.
Immunohistochemical staining was performed using antibodies to myosin 7a, phalloidin, and TO-PRO.
Results: Hair cell counts demonstrate a uniform ototoxicity model with total loss of outer hair cells (OHCs) and
near-total loss of inner hair cells (IHCs). The group pre-treated with dexamethasone showed a statistically
significant improvement in counts compared to controls (p = 0.004). Counts from the other experimental groups
given dexamethasone after the insult were highly variable but demonstrated some apical and middle turn inner
hair cell survival.
Conclusion: Treatment of systemic dexamethasone prior to ototoxic insult attenuates hair cell loss in a reliable,
novel, ototoxicity model using kanamycin and furosemide in CBA/CaJ mice. Dosing with dexamethasone following
ototoxic insult shows promising yet variable response in hair cell survival.Introduction
Administration of corticosteroids has been shown to at-
tenuate the ototoxic effects of aminoglycoside in animal
models [1-3]. These effects shown in vivo have implications
in the treatment of cochleovestibular toxicity. Corticoste-
roids are also a standard treatment modality in multiple
otologic conditions such as Meniere’s disease, sudden
sensorineural hearing loss and hearing loss secondary to
acoustic trauma. The anti-inflammatory effects of the
corticosteroids which reduce the severity of the hair cell
loss are thought to be paramount in their efficacy in the* Correspondence: Vincent.Lin@sunnybrook.ca
Department of Otolaryngolgy – Head and Neck Surgery, Sunnybrook Health
Sciences Centre, University of Toronto, 2075 Bayview Ave, Suite M1-102,
Toronto, ON M4N 3M5, Canada
© 2014 Fernandes and Lin; licensee BioMed C
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumtreatment of these conditions. Corticosteroids are also
used during cochlear implant surgery to minimize the
effect of electrode insertion trauma. In the era of ex-
panded candidacy criteria where a growing percentage
of patients have reasonable residual low frequency hear-
ing, it is important to maximize our ability to minimize
trauma to the remaining auditory hair cells and thus
preserve residual hearing.
One of the difficulties for the treating physician is that
corticosteroid dosing regiments are still quite variable and
traditionally in the role of otoprotection, they are given
prior to the initiation of treatment. It is not known if there
is any role for administrating systemic corticosteroids
after the ototoxic drug has been given. In the field of car-
diovascular medicine, the treatment of acute myocardialentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
Figure 1 Study protocol. *T0 marks the completion of ototoxic
insult. First kanamycin is injected followed by furosemide 30 min
later, at which point T0 begins. Group A received corticosteroids
1 hour prior to kanamycin injection.
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by the principle of the ‘golden hour’. If treatment is initi-
ated within an hour of symptom onset, the degree of tis-
sue death is significantly reduced and major morbidity is
lessened. In the instance of ototoxicity, our question was
whether there was a similar window of time for interven-
tion after the delivery of the ototoxic agent. Specifically,
after the ototoxic insult is given, is there a ‘golden hour’ of
time in which corticosteroid administration will either
prevent or minimize hair cell loss? The purpose of our
study is to determine whether the benefits of corticoster-
oid protection can be extended to after the ototoxic drug




Adult male CBA/CaJ mice (Jackson Laboratories, Bar
Harbor, Maine, USA) were allowed free access to water
and a regular mouse diet and were kept at room tem-
perature under a standard 12 hour light/dark cycle for
one week of acclimatization before the experiments.
Animals were between 4–5 weeks of age and of approxi-
mately 16–23 g bodyweight. All research protocols were
approved by the institutional review board at Sunny-
brook Research Institute, Sunnybrook Health Sciences
Centre, University of Toronto. Animal care was under
the supervision of the Sunnybrook Research Institute,
Sunnybrook Health Sciences Animal Facility.
Ototoxin administration
The first injection for each animal was given at the
beginning of the mice daily light cycle. Mice were ran-
domly divided into 6 groups. All intervention groups
had kanamycin (Sigma Aldrich, Oakville, ON, Canada,
Cat. No. F4381-1G) (1 mg/g) injected subcutaneously
followed by furosemide (Sigma Aldrich, Oakville, ON,
Canada, Cat. No. F4381-1G) (0.5 mg/g) injected intra-
peritoneal 30 minutes later (T0). Animals were then
kept under a heat lamp and provided 100% O2 until
they returned to normal levels of activity. Those show-
ing signs of severe dehydration or other significant
illness were euthanized. All animals were monitored
by trained animal care technologists supervised by a
veterinarian. A total of 71 mice were used.
Dexamethasone treatment
Corticosteroid rescue was administered at varying intervals
according to group at a dose of 0.1 mg/g. Group A received
dexamethasone (Sandoz, Boucherville, QC, Canada) at T-
1 hour prior to ototoxic administration (Figure 1). Group B
had dexamethasone administered at T + 1 hour post fur-
osemide injection, Group C had dexamethasone adminis-
tered 6 hours post furosemide injection, Group D haddexamethasone administered 12 hours post furosemide
injection and Group E had dexamethasone administered
72 hours post furosemide injection. The control group had
the ototoxic insult administered but no steroid rescue was
given, and served as confirmation of the ototoxicity model.
All animals were given 1 cc of normal saline subcutane-
ously on the first day following the ototoxic insult. Mice
were anaesthetized with isoflurane and sacrificed by cervical
dislocation at 7 days post-corticosteroid rescue or 7 days
after the ototoxin regiment in the control group.
Immunohistochemistry
Immediately following sacrifice, temporal bones were
dissected and placed in a 4% paraformaldehyde (Sigma
Aldrich, Oakville, ON, Canada, Cat. No. 441244-3KG)
solution for 30 minutes then stored in PBS. Organ of
Corti explants were dissected under a microscope by re-
moving the otic capsule. The remaining tissue, including
the stria vascularis, was then dissected away and the
remaining tissue containing the cochlear sensory epithe-
lium was cut into apical, second, and basal turns. The
cochlear sensory epithelium were permeabilized and blocked
in 10% normal goat serum/0.05% Triton X-100 in PBS for
1 hour at room temperature then immediately incubated
with primary myosin 7a rabbit Ab (1:250 dilution, Proteus
Biosciences Inc., CA, USA, Cat. No. 25–6790) and kept
overnight at 4°C. Specimens were then washed in 3 times
with PBS, incubated with secondary Cy3 IgG (Jackson
Immunoresearch, West Grove, PA) 1:250 dilution in PBS
for 2 hours at room temperature, then washed 3 times with
PBS. After a final wash with PBS, specimens were incubated
with phalloidin 1:250 in 0.05% Triton X-100 PBS (Sigma-
Aldrich, Oakville ON, Canada, Cat. No. P5282-1MG), for
30 minutes at room temperature then washed 3 times with
PBS. Specimens were finally incubated with TO-PRO
(Invitrogen, Burlington, ON, Canada, Cat. No. T3605)
1:500 dilution in PBS for 10 minutes then washed 3 times
in PBS. Final triple-labelled specimens were mounted on
slides with anti-fade fluorescence mounting media VECTA-
SHIELD® (Vector Laboratories, Burlington ON, Canada).
Immuno-labelled surface preparations were imaged with a
Zeiss LSM510 confocal microscope (Carl Zeiss MicroImaging
GmBH, Germany) equipped with a Spectra Physics
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USA). Confocal settings involved 63 x magnifications with
uniform settings throughout all imaging analysis.
Counting
Samples were analyzed using ImageJ (NIH, USA http://
imagej.nih.gov/ij). Inner and outer hair cells were
counted for the entire field which was standardized
and measured at 146 μm2. A cell was considered a hair
cell if there was positive myosin VII labelling and the
cell was in the appropriate level based upon TO-PRO
nuclear labelling. Inner (IHC) and outer hair cells (OHC)
were distinguished by their morphology and relative pos-
ition to their corresponding support cell.
Statistical analysis
Data was statistically evaluated by using SPSS® (V20, IBM
Corp ©). Dependent variables were analyzed with univari-
ate or multivariate analysis using LSD post-hoc test.
Results
Ototoxicity model
The combined kanamycin and furosemide protocol in
CBA/CaJ mice produced a uniform ototoxicity model of
hair cell loss. Amongst all control group mice (n = 9),
there was no OHC survival in either the basal, second
turn, or apical segments (Figure 2iii). We identified total
loss of both outer and inner hair cells in the basal turns,
as well as near total loss of IHCs amongst second and
apical turns. Only 2/9 specimens retained some IHCs in
the second turn (average: 2.86 cells/146 μm2) and 3/9
specimens retained IHCs in the apical segments (average:
1.56 cells/146 μm2). Out of the 71 used in our experiment,
42 survived for tissue analysis for a survival rate of 59.1%.
Hair cell counts
Viable samples available for analysis on slides included 6
mice from Group A, 7 mice from Group B, 4 mice fromFigure 2 i) Group D, white arrow is pointing to inner hair cell, white s
hair cells, no outer hair cells iii) group F (control), no hair cells seen.Group C, 7 mice from Group D, 7 mice from Group E,
and 7 mice from Group F and average hair cell counts
are displayed in Table 1.
A specimen not treated with the ototoxin regimen
labelled with myosin 7a and phalloidin depicts 3 rows of
OHC and 1 row of IHC in a uniform pattern (Figure 3).
In all experimental groups receiving the ototoxin regi-
men, hair cell loss was profound. In fact, only group A
demonstrated OHC survival (Figure 2ii). Group A
counts were significantly different from control groups
for the basal (F =13.59, p = 0.004) and second turn (F =
5.401, p = 0.04) but not the apex segments (F = 3.22,
p = 0.096) (Figure 4).
Counts across groups B to E were variable and demon-
strated no significant pattern amenable to analysis. Al-
most no OHCs survived despite dexamethasone across
groups. There was variable response of at most 2 OHCs
in 1–2 specimens per group surviving. IHC survival was
also variable, but almost negligible amongst basal seg-
ments. Middle and apical segments were further studied.
Univariate analysis confirmed significant differences between
control and both Group C (p=0.033) and Group E (p=0.019),
but not between Group C and Group E themselves (p=0.908).
Group D (+12 hr) paradoxically had lower hair cell counts
than groups C and E, with only a few hair cells surviving
(Figure 2i). No other differences were found between
other time point groups and control in terms of OHC
survival, or IHC survival in the basal or second turn levels,
including when all HC counts were combined and
compared across groups (Figure 5).
Discussion
The otolaryngologist - head & neck surgeon routinely
faces an uncertain decision point following consultation
for acute cochleovestibular toxicity. For example, effective
aminoglycoside therapy in our inpatient units has well
known side effects, including cochlear and vestibular
toxicity thought to be irreversible and permanent. Exposurecale bar is 10 microns ii) group A, white arrow pointing to inner
Table 1 Average hair cell counts per standard field
Group A (−1 Hr prophylactic) Group B (+1 Hr) Group C (+6 Hr) Group D (+12 Hr) Group E (+72 Hr) Control
Basal turn IHC 7.83 0 0 2.5 2.5 0
2nd turn 6.17 5.20 3.5 0.17 5.43 2.86
Apical turn 5.67 0.4 11.75 2.5 9.83 1.56
Basal OHC 16.33 0.43 0 0 0.25 0
2nd turn 2.17 1.20 0 0 0 0
Apical turn 1 0 0.25 0.25 0 0
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or vestibular hair cells usually resulting in permanent
hearing loss or vertigo. The otolaryngologist is then asked
whether intervention is indicated in the acute stage after
the drugs are given to minimize or reverse the damage. Fur-
ther related clinical scenarios involve patients with sudden
sensorineural hearing loss presenting to our emergency
room. If the patient presents late to the ER, such as several
days following the initial recognition of hearing loss, the
question will often be asked as to whether steroids should
still be recommended. For both these scenarios, there is no
research that has examined the effect that timing of admin-
istration has on attenuating hair cell loss.
Aminoglycosides have long been known to have oto-
toxic effects. Some, like gentamicin, have a more vesti-
bulotoxic profile, while others such as kanamycin have aFigure 3 Normal CBA/CaJ mice. White arrow indicates normal
inner hair cells (IHC). Yellow arrow indicates normal outer hair cells
(OHC). White bar represents 10 microns.more cochleotoxic profile, which is one of the reasons it
was chosen for our experiments. Currently, aminoglyco-
sides are used in auditory research to eradicate hair cells
in studies of hair cell regeneration [4]. This class of
drugs primarily targets the basal hair cells with a prefer-
ence for outer hair cells versus inner hair cells. Other ef-
fects on the cochlea include clumping of stereocilia, bleb
formation, and diminished glycocalyx [5,6]. Although the
precise mechanism of aminoglycoside induced auditory
hair cell loss is unclear, there is evidence that the forma-
tion of reactive oxygen species induces hair cell apoptosis
[7,8]. Aminoglycosides can trigger free radial formation
that mediates cellular damage. Long-term aminoglycoside
administration is further associated with extension of the
loss towards the apical hair cells and/or inner hair cell loss.
While aminoglycoside alone has been shown to induce
hair cell loss in many animal models, murine ototoxicity
models have been shown to be highly ineffective if using
aminoglycosides alone [9]. In fact, the dose of kanamycin
required to produce ototoxic effects are much higher
than in rats and guinea pigs, for reasons that might in-
clude pharmacokinetics, bioavailability and activation of
the drug. However, synergism with furosemide has been
shown to increase the toxic effect, and create more reliableFigure 4 Comparison of hair cell counts between control group
and group A given dexamethasone 1 hour prior to ototoxic
insult. *indicates a statistically significant difference.
Figure 5 Average inner hair cell counts combining all samples.
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models to our knowledge involve daily injections over
multiple days. The mechanism by which the loop di-
uretics exacerbate aminoglycoside-induced hearing loss
and HC damage is unclear. However, one of the leading
hypotheses, given the inhibition by loop diuretics of Na/
K/2CL co-transporters, involves a drop in the endoco-
chlear potential that causes a loss of the electrochemical
gradient that drives transduction current through hair
cells, increasing hearing thresholds and increasing their
susceptibility towards apoptosis [12].
Our study employed dexamethasone as a rescue agent.
Administration of dexamethasone has been well docu-
mented in the attenuation of hair cell apoptosis in animal
models, particularly in guinea pig models of apoptosis
[13,14]. Himano demonstrated that local administration of
dexamethasone directly to the inner ear preceding amino-
glycoside administration attenuated hair cell loss. Dexa-
methasone acts primarily as a glucocorticoid rather than
mineralocorticoid, which modulates inflammation and im-
mune responses, and locally increases cochlear blood flow
[15]. The efficacy of its otoprotection is related to dosing
regimens [16]. Thus, we used very high doses of dexa-
methasone in our experiments in order to control and
maximize our dose response. However, as a result, the
doses are not generalizable across species. Nevertheless,
previous findings have confirmed that high dose systemic
administration resulted in strong dexamethasone labelling
of hair cells [17]. Although our high dosing regimen elimi-
nated a dose–response effect, further studies of the effect
of timing with varying doses and routes administration of
dexamethasone would be extremely valuable.
Ototoxic regiment is highly effective in ablating both
inner and outer hair cells
This paper examines the effect of timing of steroid adminis-
tration following ototoxic insult. We present a robust
ototoxicity model using kanamycin/furosemide to establishconsistent near complete OHC loss and high IHC loss in
the CBA/CaJ mouse using a newly described single day
injection model. Our objective was to establish a rapid
systemic protocol for elimination of sensory hair cells in
adult mice. This regimen was based on experiments done
in other mammals combining aminoglycosides and a loop
diuretic [18]. This technique was further described in CBA/
CaJ + Swiss-Webster murine model by Oesterle (2008) [19]
and validated in a C57BL/6 murine model by Hartman
(2009) [20], both of whom used doses of kanamycin
(1 mg/g) and furosemide (0.4 mg/g). While these protocols
describe total OHC loss similar to our findings, both proto-
cols report IHCs to be largely intact. Taylor employed a
similar single injection model in CBA mice using kanamy-
cin with the loop diuretic bumetanide, and showed via ami-
noglycoside tracers that kanamycin does in fact enter IHCs
[21]. The IHC survival rate in this model was still relatively
high at 50%. Our model uses a higher variant dose of fur-
osemide (0.5 mg/g) and in an adult CBA/CaJ murine model
that establishes a rapid, robust method of destroying both
outer and inner hair cells. In fact, we achieved total (100%)
IHC loss in 2/3 of control specimens, with the remaining
1/3 only retaining up to 30% of IHCs. This consistency of
hair cell loss provides a more reliable and sensitive model
that can be used to detect small levels of otoprotection.
This model translates clinically only to those patients that
demonstrate severe symptoms and effects of ototoxicity
and likely represents a small percentage of patients that
suffer ototoxicity. The majority of these patients likely have
milder symptoms and effects. We decided to not aim for a
smaller damage model due to the potential for highly vari-
able results in the control damage group and the reduction
in sensitivity that it would provide for our corticosteroid
otoprotection regiment.
Prophylactic treatment with corticosteroids protects
mainly inner hair cells and basal outer hair cells
Mice treated with dexamethasone prior to the ototoxic
insult had significantly higher cell counts in their basal
and second turns. There were large differences between
the prophylactic group (Group A) and control group
(Group F) that were not as extreme as with the other
groups. Paradoxically, there was no statistical difference
found in the apical layers, however a clear trend toward
greater survival in the prophylactic group was present. It
is unclear why we did not see greater differences in the
apical segment as expected. Aminoglycosides have been
shown in animal studies to be in the stria vascularis and
spiral ligament soon after administration, and accor-
dingly thought to enter the cochlea through the vascu-
lature [22]. It may be that a uniform concentration of
aminoglycosides within the cochlea enters via the coch-
lear vasculature interacting with a decreasing basal to
apical gradient of dexamethasone uptake demonstrated
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protective corticosteroid effect to be only detectable in
the basal and second turns.
Corticosteroid rescue is effective in some groups but its
effect is highly variable
Counts of hair cells in the Organ of Corti following steroid
rescue at varying intervals following ototoxic insult demon-
strate a protective effect of prophylactic administration of
dexamethasone as well a trend toward IHC protection in
the apical turn but there was large variability within diffe-
rent treatment groups so trends can be seen but clear pat-
terns cannot be established. However, the preservation of
some apical IHCs in groups C and E, and middle turn IHCs
in groups B,C and E despite the corticosteroids adminis-
tered after the ototoxic insult demonstrates the potential,
albeit, variable potential corticosteroids offer in protecting
auditory hairs from undergoing apoptosis.
Limitations of study
While we have used auditory hair cell counts as a marker
for cochlear function, there are limits to this model. We did
not assess the status of the auditory nerve or measure
function via either evoked brainstem responses (ABR) or
otoacoustic emissions (OAE). It would have been helpful to
assess the viability of hair cells at earlier time points rather
than simply 7 days post corticosteroid administration. In
fact Himeno’s work demonstrated that dexamethasone
allowed for hair cell protection but had little effect on hea-
ring preservation [2]. Yet, when damaged hair cells initiate
the process of apoptosis, the process has been shown in
animal models to be attenuated by corticosteroid adminis-
tration. Therefore we can infer that higher hair cell counts
than expected following ototoxin administration indicate
a protective effect of steroids in at least one part of the
auditory pathway, the Organ of Corti.
CBA/CaJ mice have limited genetic variation as they
are inbred. Further, they have been shown to have in-
creased susceptibility to kanamycin compared to other
murine inbred models such as C57BL6 mice, particularly
with age. Accordingly, likely only little of the variability
in our results can be explained by genetic variation.
Only prophylactic treatment with corticosteroids prior to
ototoxic insult was demonstrated to have any consistent
effect in achieving auditory hair cell survival. Our study
employed an ototoxic model that resulted in total hair cell
loss in the basal segments of mice, as well as near total hair
cell loss in the second turn and apical segments. Given the
severe loss, our findings are consistent with what we know
of clinical scenarios such as those patients who present with
sudden sensorineural hearing loss. Poor prognostic factors
include severity of loss, suggesting that if the insult is severe
enough there may be a threshold that once crossed can-
not be reversed. Similar situations exist for brain injury,myocardial infarction and hypoxic injury. Future studies
are needed to explore the timing effect of therapy on an
ototoxicity model that imparts incomplete yet reliable
of hair cell loss which is the equivalent to those patients
with a partial threshold shift on auditory testing. These
types of patients are more common than those initially
presenting with a complete sensorineural loss.
Conclusion
The administration of kanamycin and furosemide at a
single time point provides a reliable ototoxicity model
in CBA/CaJ mice. Prophylactic treatment with dexa-
methasone prior to ototoxic administration attenuates
hair cell loss. There is some evidence that the timing of
administration of steroid rescue influences hair cell sur-
vival but the high degree of variability makes definitive
conclusions challenging.
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